The period 2023 - 2027 looks to be exciting for the new Danish Diabetes and Endocrine Academy (DDEA), as it receives a grant of 195 mio DKK (26 mio EUR) from the Novo Nordisk Foundation for the five-year period. The new academy builds on the Danish Diabetes Academy (DDA) with an expanded focus to the entire field of endocrinology. The academy is located at Odense University Hospital.

DDEA’s mission is to foster early-career research talent in diabetes and endocrinology through grants, education, talent development, networking, and national and international collaborations across research fields with academia, hospitals, and the life science industry and NGOs. DDEA will offer courses, symposia, workshops, and other educational events for early-career researchers.

The strategy behind DDEA is made in collaboration between representatives from universities, university hospitals, the life-science industry, and Danish Endocrine Society (DES).

“The Danish Diabetes and Endocrine Academy aims to support the ability of talented young researchers to perform high-quality research, as well as enhancing their professionalism through education, networking, and collaborations. In the long term, we expect this to lead to significantly improved prevention and treatment strategies benefiting people with or at risk of diabetes and other endocrine diseases,” said Martin Ridderstråle, Senior Vice President of Medical Science of the Novo Nordisk Foundation.

The DDEA is a continuation and a further development of the Danish Diabetes Academy (DDA), which the Novo Nordisk Foundation has supported with a total of DKK 357 million since its inception in 2012.

“We are very proud and happy that the Novo Nordisk Foundation recognises our impact on Danish research by granting us the means to widen our scope even further and continue as a whole new academy,” says DDA chair of the board Allan Flyvbjerg.